AU2021233176A1 - Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo - Google Patents

Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo Download PDF

Info

Publication number
AU2021233176A1
AU2021233176A1 AU2021233176A AU2021233176A AU2021233176A1 AU 2021233176 A1 AU2021233176 A1 AU 2021233176A1 AU 2021233176 A AU2021233176 A AU 2021233176A AU 2021233176 A AU2021233176 A AU 2021233176A AU 2021233176 A1 AU2021233176 A1 AU 2021233176A1
Authority
AU
Australia
Prior art keywords
conjugate
yrgd
frgd
tyr
atomic group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021233176A
Other languages
English (en)
Inventor
Johannes NOTNI
Neil QUIGLEY
Katja STEIGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Publication of AU2021233176A1 publication Critical patent/AU2021233176A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AU2021233176A 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo Pending AU2021233176A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20162699.1 2020-03-12
EP20162699 2020-03-12
PCT/EP2021/056424 WO2021180969A1 (en) 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo

Publications (1)

Publication Number Publication Date
AU2021233176A1 true AU2021233176A1 (en) 2022-09-08

Family

ID=69810651

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021233176A Pending AU2021233176A1 (en) 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo

Country Status (11)

Country Link
US (1) US20230173113A1 (https=)
EP (1) EP4117736A1 (https=)
JP (1) JP7787083B2 (https=)
KR (1) KR20220152322A (https=)
CN (1) CN115297893B (https=)
AU (1) AU2021233176A1 (https=)
BR (1) BR112022016986A2 (https=)
CA (1) CA3175061A1 (https=)
IL (1) IL296081A (https=)
MX (1) MX2022011287A (https=)
WO (1) WO2021180969A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections
WO2025218677A1 (zh) * 2024-04-16 2025-10-23 中山医诺维申新药研发有限公司 双重靶向成纤维细胞激活蛋白和整合素亚型的化合物及其制备和应用
WO2026027771A1 (en) 2024-08-02 2026-02-05 Trimt Gmbh Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
CA2937753A1 (en) 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
SI3350222T1 (sl) 2015-09-18 2022-01-31 Technische Universitaet Muenchen Ligandi za integrin avbeta6, sinteza in uporaba le-teh
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
CA3090196A1 (en) 2018-02-06 2019-08-15 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Compound for intraoperative molecular bioimaging, method of making the same, use thereof in intraoperative molecular bioimaging and surgical method comprising intraoperative molecular bioimaging

Also Published As

Publication number Publication date
KR20220152322A (ko) 2022-11-15
JP2023518161A (ja) 2023-04-28
CA3175061A1 (en) 2021-09-16
MX2022011287A (es) 2022-12-08
CN115297893B (zh) 2025-09-23
JP7787083B2 (ja) 2025-12-16
US20230173113A1 (en) 2023-06-08
WO2021180969A1 (en) 2021-09-16
CN115297893A (zh) 2022-11-04
EP4117736A1 (en) 2023-01-18
BR112022016986A2 (pt) 2022-10-25
IL296081A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
JP5676673B2 (ja) 癌の画像化および処置
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
CA3090812A1 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
Medina et al. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide
BRPI0909823B1 (pt) Conjugados antagonistas de peptídeo análogo de bombesina, seu uso e seu processo de preparação, composição farmacêutica, processo para formação de imagem de receptores de bombesina e kit
US20210330819A1 (en) Design and development of neurokinin-1 receptor-binding agent delivery conjugates
US20230173113A1 (en) Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo
CA3171753A1 (en) Stable formulations for radionuclide complexes
WO2019092242A1 (en) A double-labeled probe for molecular imaging and use thereof
US12485191B2 (en) Radiopharmaceuticals and methods of use thereof
KR20250065913A (ko) Rgd 이량체 화합물 및 이의 제조 방법과 응용
JP2004524323A (ja) 結腸直腸癌診断のためのテトラデンテートペプチド−キレートコンジュゲート
Hirata et al. Synthesis and evaluation of a multifunctional probe with a high affinity for prostate-specific membrane antigen (PSMA) and bone
Gaonkar et al. Development of a peptide-based bifunctional chelator conjugated to a cytotoxic drug for the treatment of melanotic melanoma
US7481993B2 (en) Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
TW202541853A (zh) 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
CA3224462A1 (en) Ligand compounds comprising a chelating group as a bridging group
PT1590317E (pt) Áçido (4s, 8s) - e (4r, 8r) -4-p-nitrobenzil-8-metil-3, 6, 9, triaza-sp 3/sp n, sp 6/sp n, sp 9/sp n-tricarboximetil-1, 11-undecanóico enantiomericamente puro e seus derivados, processo para a sua preparação e utilização para a preparação de agentes
EP1700608A1 (en) Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
CA3258869A1 (en) ZWITTERIONIC COMPOUNDS AND THEIR USES
WO2024046469A1 (zh) 环肽及其制备方法、包括其的复合物、及其用途
WO2025191096A1 (en) Bicyclic peptide
WO2005110497A1 (en) Imaging of tumors and metastases using a gelatinase targeting peptide comprising the structure ctthwgftlc.